04, 2021 (GLOBE NEWSWIRE) - Arcutis Biotherapeutics, Inc. Strong financial position with approximately $370 million in cash, cash equivalents, and marketable securities, providing cash runway well into 2023.Expanded patent portfolio with issuance of first pharmacokinetics patent covering both the cream and foam formulations of topical roflumilast.Enrolling pivotal Phase 3 trials of roflumilast cream in atopic dermatitis and roflumilast foam in seborrheic dermatitis.Initiated single pivotal Phase 3 trial of roflumilast foam in scalp and body psoriasis.Submitted New Drug Application (NDA) for roflumilast cream for the treatment of plaque psoriasis across the full spectrum of disease.
